Chemotherapy-Induced Peripheral Neuropathy, Anxiety, Depression, and Quality of Life in Lung Cancer Patients Receiving Chemotherapy

Friday, 26 July 2019

Hsing-Wei Hung, MSN, RN
Department of Nursing, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan
Shu-Ching Chen, PhD, RN
Department of Nursing, Chang Gung University of Science and Technology, Taoyuan, Taiwan

Background: Chemotherapy-induced peripheral neuropathy is a common adverse event occurring in patients who receive some chemotherapeutic agents. The symptoms are mainly sensory or motor nerve conduction problems, which may cause the patient physical and psychological distress and have a negative impact on the quality of life (QOL).

Purpose: The aim of the current study was as follows: (1) explore symptoms associated with distress, anxiety, depression, and chemotherapy-induced peripheral neuropathy and health-related QOL; (2) explore the correlations between demographic characteristics, disease characteristics, anxiety, depression, and QOL; and (3) identify the predictors of QOL.

Methods: A cross-sectional, correlational study was conducted. Patients were assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chemotherapy-induced Peripheral Neuropathy 20 (EORTC QLQ-CIPN20), the Hospital Anxiety and Depression Scale (HADS), the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx), the Functional Assessment of Cancer Therapy-Lung(FACT-L),and a background information form. Patients were recruited from four chest medicine wards for advanced lung cancer in a medical center in northern Taiwan. Data were analyzed by descriptive analysis, Pearson’s product-moment correlation, and multiple regression. A total of 67 advanced lung cancer patients were recruited for this study.

Results: (1) a significant negatively correlation was found among chemotherapy-induced peripheral neuropathy QOL, grade of peripheral neuropathy, peripheral neuropathy symptom distress, and depression, while chemotherapy-induced peripheral neuropathy QOL was positive correlated with physical well-being; (2) a significant positive correlation was found among health-related QOL, age, physical well-being, social/family well-being, emotional well-being, and functional well-being, while health-related QOL was negatively correlated with anxiety and depression; (3) stepwise regression showed that peripheral neuropathy symptom distress predicts chemotherapy-induced peripheral neuropathy QOL, with 62.7% explained variance; and (4) age, physical well-being, and anxiety predict health-related QOL, with 46.9% explained variance.

Conclusion: The results of this study can help healthcare providers understand the issues and predictors of chemotherapy-induced peripheral neuropathy QOL in patients with advanced lung cancer, provide effective and individualized health education in a timely fashion, and provide a reference for clinical care.